← Browse by Condition
Medical Condition
pulmonary hypertension
Total Trials
10
Recruiting Now
10
Trial Phases
Phase 3, Phase 2
Hypertension remains the most common treatable cardiovascular risk factor globally, yet blood pressure control rates remain suboptimal despite multiple effective drug classes. Clinical trials now investigate novel mechanisms including aldosterone synthase inhibitors, renal denervation devices, and RNA-based therapies targeting angiotensinogen to achieve durable pressure reduction with minimal pill burden.
Active research includes zilebesiran (RNA interference targeting angiotensinogen), baxdrostat (aldosterone synthase inhibitor), ultrasound renal denervation (Symplicity HTN-4), and resistant hypertension approaches combining SGLT2 inhibitors with MRA spironolactone. Ambulatory blood pressure monitoring is increasingly used as the primary endpoint instead of clinic readings.
Frequently Asked Questions — pulmonary hypertension Clinical Trials
How many clinical trials are currently recruiting for pulmonary hypertension?
ClinicalMetric currently tracks 10 actively recruiting clinical trials for pulmonary hypertension, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 10. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for pulmonary hypertension?
pulmonary hypertension research spans Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a pulmonary hypertension clinical trial?
Eligibility criteria for pulmonary hypertension trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2 1
Phase 3 1
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07453017
Recruiting
Enrollment
120 pts
Location
Brazil
Sponsor
University of Sao Paulo Genera...
NCT05566002
Recruiting
Enrollment
2,000 pts
Location
China
Sponsor
Chinese Pulmonary Vascular Dis...
NCT04993612
Recruiting
Enrollment
100 pts
Location
Germany
Sponsor
Ayham Daher
NCT06129240
Recruiting
Enrollment
80 pts
Location
United States
Sponsor
Liquidia Technologies, Inc.
NCT07563322
Recruiting
Enrollment
10 pts
Location
United States
Sponsor
Vanderbilt University Medical ...
NCT06362382
Recruiting
Enrollment
80 pts
Location
China
Sponsor
China-Japan Friendship Hospita...
NCT06495970
Recruiting
Enrollment
20 pts
Location
Spain
Sponsor
Gradient Denervation Technolog...
NCT07187206 Phase 3
Recruiting
Enrollment
75 pts
Location
United States
Sponsor
Children's Hospital Medical Ce...
NCT07333183 Phase 2
Recruiting
Enrollment
20 pts
Location
United States
Sponsor
Pulmovant, Inc.
NCT03269630
Recruiting
Enrollment
450 pts
Location
United States
Sponsor
Louisiana State University Hea...
Related Conditions
pulmonary thromboembolisms (1) pulmonary arterial hypertension (1) interstitial lung disease (1) congenital diaphragmatic hernia (1) pulmonary hypoplasia (1) interstitial lung disease ild (1) lung diseases (1) vascular diseases (1) cardiovascular diseases (1) fibrosis (1) systemic sclerosis (1) mixed connective tissue disease (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology